Cencora

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Is Cencora Stock Underperforming the Dow? - Barchart.com

AI-generated analysis

πŸ“ˆ COR stock has risen 18.5% over the past three months, outperforming the Dow Jones Industrial Average's 3.9% gain during the same period.

πŸ“‰ Over the last 52 weeks, COR shares have surged 9%, lagging behind the Dow's 16% gain and significantly underperforming peer Cardinal Health, Inc., which has grown 60%.

πŸ’° Cencora reported Q3 2026 revenue of $84.8 billion, which missed Street estimates, but adjusted EPS of $4.48 topped Wall Street forecasts.

πŸ“Š Following the earnings release, COR shares rose 3.6%, indicating positive market reaction to the beat in profitability despite the revenue miss.

🎯 Analysts covering Cencora maintain a consensus 'Strong Buy' rating with a mean price target of $366.50, implying 12.9% upside potential.

πŸ“‰ The stock has underperformed its primary peer Cardinal Health, Inc., which has seen a 60% stock price increase over the past year.

Bullish Signals
  • COR stock has risen 18.5% over the past three months, significantly outperforming the Dow Jones Industrial Average's 3.9% gain during the same period.
  • The company reported adjusted EPS of $4.48 for Q3 2026, which topped Wall Street forecasts despite revenue missing estimates.
  • Following the earnings release, COR shares rose 3.6%, demonstrating immediate positive investor reaction to the profitability beat.
  • Analysts maintain a consensus 'Strong Buy' rating with a mean price target of $366.50, suggesting 12.9% upside from current levels.
Risk Factors
  • COR stock has underperformed the Dow Jones Industrial Average over the past 52 weeks, surging only 9% compared to the index's 16% gain.
  • The company significantly lags behind its major peer Cardinal Health, Inc., which has grown 60% in stock price over the past year.
Full Analysis
Cencora, Inc. (COR) is a large-cap pharmaceutical distributor based in Conshohocken, Pennsylvania, with a market capitalization of $61.6 billion. The company sources and distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies to acute care hospitals and health systems both domestically and internationally. Recent stock performance shows mixed results depending on the timeframe. Over the past three months, COR shares have risen 18.5%, outperforming the Dow Jones Industrial Average which grew 3.9% during the same period. However, over the last 52 weeks, the stock has surged only 9%, lagging behind the Dow's 16% gain and significantly underperforming its peer Cardinal Health, Inc., which has grown 60% in the past year. Following the release of Q3 2026 earnings, COR shares rose 3.6%. The company reported quarterly revenue of $84.8 billion, which missed Wall Street estimates, but adjusted earnings per share (EPS) of $4.48 exceeded forecasts. Analysts maintain a consensus 'Strong Buy' rating with a mean price target of $366.50, suggesting 12.9% upside from current levels.